Immugenia Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2022

Location

QC Canada

Primary Industry

Healthcare Specialists

About

Based in Canada, and founded in 2022 by its CEO Stéphane Gagné and co-founder Brigitte Lemieux, Immugenia Inc. operates as an early-stage immuno-oncology company that develops CAR therapy. In October 2022, Immugenia Inc. raised venture funding from ACET Capital, adMare Bioinnovations and Sherbrooke Innopole. Immugenia Inc. develops CAR (chimeric antigen receptor) therapy which involves immune cells from a cancer patient and modifying them to express a CAR, making it possible to recognize and kill cancer cells when injected back into the patient. Its technology allows for the CAR to be expressed selectively in T and NK cells in order to leverage their synergistic activity against cancer. In addition, the company has created a biotechnological tool enabling the use of hematopoietic stem cells to treat life-threatening cancers. The company plans to use venture funding to develop a cancer treatment which would prevent relapses.

Current Investors

adMare Bioinnovations, Sherbrooke Innopole, ACET Capital

Request a demo to show more

Primary Industry

Healthcare Specialists

Sub Industries

Biotechnology, Oncology/Cancer Treatment, Medical Software

Website

www.immugenia.com

Verticals

HealthTech

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.